atreca

Biopharma firm Atreca goes public

Biopharma firm Atreca goes public

Atreca uses its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types.

Atreca Raises $125 Million

Atreca Raises $125 Million

Atreca was one of the first companies in Mission Bay Capital’s portfolio.

Big Pharma ally Atreca scoops $35M as I-O assets near IND

Big Pharma ally Atreca scoops $35M as I-O assets near IND

Atreca was an early portfolio company of QB3-affiliated Mission Bay Capital.

Atreca and Dana-Farber to partner on cancer immunotherapy

Atreca and Dana-Farber to partner on cancer immunotherapy

Atreca will apply its Immune Repertoire Capture® technology to generate sequences of native antibodies and TCRs from patients.